Survey

ATRIAL FIBRILLATION
Challenges and Opportunities for the Consultant Pharmacist

Now that you have completed this educational activity, please help us assess its effectiveness. Please note: THIS IS NOT THE POST-TEST.

Please indicate your profession:

Please indicate your profession: Clinical Pharmacist

Consultant Pharmacist

Retail Pharmacist

Staff Pharmacist

VA Pharmacist

Other (please specify)

Please rate your level of agreement with the following:

	Strongly Agree 6	5	4	3	2	Strongly Disagree 1
Due to potential toxicities associated with anti-arrhythmic drug therapy, older individuals with chronic AF and multiple chronic co-morbidities should be managed with rate control instead of rhythm control.	Due to potential toxicities associated with anti-arrhythmic drug therapy, older individuals with chronic AF and multiple chronic co-morbidities should be managed with rate control instead of rhythm control. Strongly Agree 6	Due to potential toxicities associated with anti-arrhythmic drug therapy, older individuals with chronic AF and multiple chronic co-morbidities should be managed with rate control instead of rhythm control. 5	Due to potential toxicities associated with anti-arrhythmic drug therapy, older individuals with chronic AF and multiple chronic co-morbidities should be managed with rate control instead of rhythm control. 4	Due to potential toxicities associated with anti-arrhythmic drug therapy, older individuals with chronic AF and multiple chronic co-morbidities should be managed with rate control instead of rhythm control. 3	Due to potential toxicities associated with anti-arrhythmic drug therapy, older individuals with chronic AF and multiple chronic co-morbidities should be managed with rate control instead of rhythm control. 2	Due to potential toxicities associated with anti-arrhythmic drug therapy, older individuals with chronic AF and multiple chronic co-morbidities should be managed with rate control instead of rhythm control. Strongly Disagree 1

Please choose the most appropriate answer:

Mr. L. is a 76-year old man with persistent AF and a history of coronary artery disease. He has no evidence of hypertension, heart failure, diabetes, or any recent strokes or transient ischemic attacks (TIAs).

What is his CHADS risk score?

Please choose the most appropriate answer:

Mr. L. is a 76-year old man with persistent AF and a history of coronary artery disease. He has no evidence of hypertension, heart failure, diabetes, or any recent strokes or transient ischemic attacks (TIAs).

What is his CHADS risk score? Not sure

1-2

3-4

5-8

Which of the following would you recommend for this patient?

Which of the following would you recommend for this patient? Anti-arrhythmic drug therapy with dofetilide, dronedarone, sotalol, or amiodarone

Anti-arrhythmic drug therapy with dofetilide, dronedarone, sotalol

Anti-arrhythmic drug therapy with flecainide or propafenone

I would not recommend anti-arrhythmic drug therapy

What do you feel is the biggest challenge in the management of older adults with AF who reside in LTC settings?

What do you feel is the biggest challenge in the management of older adults with AF who reside in LTC settings? The risk of bleeding with anti-coagulation

Toxicities associated with drug therapy

Monitoring drug dosing and efficacy

Drug-drug interactions with drug therapy

Thank you for completing the survey. Once you click "done" your results will be submitted and you will be taken to the post-test and evaluation.

Please indicate your profession:

Please choose the most appropriate answer: Mr. L. is a 76-year old man with persistent AF and a history of coronary artery disease. He has no evidence of hypertension, heart failure, diabetes, or any recent strokes or transient ischemic attacks (TIAs). What is his CHADS risk score?

Which of the following would you recommend for this patient?

What do you feel is the biggest challenge in the management of older adults with AF who reside in LTC settings?

Please choose the most appropriate answer:

Mr. L. is a 76-year old man with persistent AF and a history of coronary artery disease. He has no evidence of hypertension, heart failure, diabetes, or any recent strokes or transient ischemic attacks (TIAs).

What is his CHADS risk score?